NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

This trial did not fail to meet PFS, the original primary endpoint because it became clear during the trial, that PFS, a surrogate of OS, has failed miserably as an adequate endpoint in this trial and is most likely an unsuitable endpoint for other immunotherapeutic trials. While it often takes much longer to obtain the OS results, those results have an accuracy of 100% in establishing at any timeline, the number of patients alive and the number of patients who are deceased. The same cannot be said for PFS even when this endpoint is employed in chemotherapeutic trials.